These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 28270010

  • 21. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY.
    Eur J Med Chem; 2021 Apr 15; 216():113265. PubMed ID: 33652352
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 15; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 15; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y, Wang J, Zhu S, Tu ZC, Zhang Z, Chan S, Ding K.
    Eur J Med Chem; 2020 Oct 01; 203():112552. PubMed ID: 32702585
    [Abstract] [Full Text] [Related]

  • 30. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
    El-Nassan HB, Al-Qadhi MA.
    Eur J Med Chem; 2023 Oct 05; 258():115618. PubMed ID: 37413881
    [Abstract] [Full Text] [Related]

  • 31. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
    Wilding CP, Loong HH, Huang PH, Jones RL.
    Curr Opin Oncol; 2020 Jul 05; 32(4):307-313. PubMed ID: 32541318
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
    Panchal I, Tripathi RKP, Parmar K, Yadav MR.
    Curr Top Med Chem; 2024 Jul 05; 24(1):3-30. PubMed ID: 38058091
    [Abstract] [Full Text] [Related]

  • 38. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 05; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 39. 5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: a selective dual inhibitor for potential PET imaging of Trk/CSF-1R.
    Bernard-Gauthier V, Schirrmacher R.
    Bioorg Med Chem Lett; 2014 Oct 15; 24(20):4784-90. PubMed ID: 25257201
    [Abstract] [Full Text] [Related]

  • 40. [Back from ASCO 2019: Advances on NTRK inhibitors in childhood tumors].
    Doz F.
    Bull Cancer; 2019 Oct 15; 106(7-8):615-616. PubMed ID: 31272686
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.